Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study on COgnition and Prognosis in the Elderly (SCOPE).

L Hansson1, H Lithell, I Skoog

  • 1University of Uppsala, Department of Public Health, Sweden.

Blood Pressure
|December 14, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[On a new technic for the study of cholesterol in alpha and beta lipoproteins].

Revue medicale de France·2014
Same author

[Aldosterone and its antagonists in heart failure].

Presse medicale (Paris, France : 1983)·2003
Same author

[Critical reading for studies on antithrombotic medications in acute coronary syndromes].

Archives des maladies du coeur et des vaisseaux·2002
Same author

[Hospital mortality in cardiology. Analysis of deaths occurring in the Federation of Cardiology of a university hospital center].

Archives des maladies du coeur et des vaisseaux·2002
Same author

Effect of carvedilol on survival in severe chronic heart failure.

The New England journal of medicine·2001
Same author

Altered baroreflex gain during voluntary breathing in chronic heart failure.

European journal of heart failure·2001

The SCOPE trial investigated candesartan cilexetil for mild hypertension in elderly patients. It assessed cardiovascular events, cognitive function, and mortality, providing key insights into hypertension management in seniors.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Mild hypertension in the elderly is common, posing significant cardiovascular risks.
  • Effective management strategies are crucial to improve prognosis and quality of life in this demographic.

Purpose of the Study:

  • To evaluate the efficacy of candesartan cilexetil versus placebo in reducing major cardiovascular events in elderly patients with mild hypertension.
  • To assess the impact of candesartan cilexetil on cognitive function, mortality, and health economics.

Main Methods:

  • A multicentre, prospective, randomized, double-blind, parallel-group study (SCOPE) involving 4964 elderly patients (70-89 years).
  • Patients received either candesartan cilexetil or placebo, with dosage adjustments based on blood pressure.

Related Experiment Videos

  • Primary endpoint: major cardiovascular events. Secondary endpoints included cognitive function, mortality, and quality of life.

    • Main Results:

    • Recruitment completed with 4964 randomized patients.
    • Follow-up duration is 2 years, potentially longer if event rates are low.
    • The study aims to provide comprehensive data on the benefits and risks of candesartan cilexetil in this population.

    Conclusions:

    • The SCOPE study provides valuable data on the cardiovascular and cognitive effects of candesartan cilexetil in elderly hypertensive patients.
    • Findings will inform clinical practice regarding hypertension management in older adults.
    • Further analysis will elucidate the drug's impact on mortality, renal function, and health economics.